Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wi...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-08-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39 |
| _version_ | 1798037009639407616 |
|---|---|
| author | Qing ZHOU Shun LU Yong LI Fujun JIA Guanjun LI Zhen HONG You LU Yun FAN Jianying ZHOU Zhe LIU Juan LI Yi-Long WU Chinese Thoracic Oncology Group (CTONG) Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup |
| author_facet | Qing ZHOU Shun LU Yong LI Fujun JIA Guanjun LI Zhen HONG You LU Yun FAN Jianying ZHOU Zhe LIU Juan LI Yi-Long WU Chinese Thoracic Oncology Group (CTONG) Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup |
| author_sort | Qing ZHOU |
| collection | DOAJ |
| description | Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy. |
| first_indexed | 2024-04-11T21:20:50Z |
| format | Article |
| id | doaj.art-eb8c36da04654724b9ff0d514ca68737 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-11T21:20:50Z |
| publishDate | 2022-08-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-eb8c36da04654724b9ff0d514ca687372022-12-22T04:02:38ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872022-08-0125855556610.3779/j.issn.1009-3419.2022.101.39Chinese Expert Consensus on Management of Special Adverse Effects
Associated with LorlatinibQing ZHOU0Shun LU1Yong LI2Fujun JIA3Guanjun LI4Zhen HONG5You LU6Yun FAN7Jianying ZHOU8Zhe LIU9Juan LI10Yi-Long WU11Chinese Thoracic Oncology Group (CTONG)Chinese Expert Consensus on Management of
Special Adverse Effects Associated with Lorlatinib WorkgroupGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaDepartment of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, ChinaDepartment of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Psychiatry, Guangdong Mental Health Center, Guangzhou 510120, ChinaDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Oncology, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, ChinaDepartment of Respiratory Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, ChinaDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, ChinaDepartment of Oncology, Sichuan Cancer Hospital, Chengdu 610041, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaAnaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy.http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39anaplastic lymphoma kinaselung neoplasmslorlatinibadverse event |
| spellingShingle | Qing ZHOU Shun LU Yong LI Fujun JIA Guanjun LI Zhen HONG You LU Yun FAN Jianying ZHOU Zhe LIU Juan LI Yi-Long WU Chinese Thoracic Oncology Group (CTONG) Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Chinese Journal of Lung Cancer anaplastic lymphoma kinase lung neoplasms lorlatinib adverse event |
| title | Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib |
| title_full | Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib |
| title_fullStr | Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib |
| title_full_unstemmed | Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib |
| title_short | Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib |
| title_sort | chinese expert consensus on management of special adverse effects
associated with lorlatinib |
| topic | anaplastic lymphoma kinase lung neoplasms lorlatinib adverse event |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39 |
| work_keys_str_mv | AT qingzhou chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT shunlu chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT yongli chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT fujunjia chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT guanjunli chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT zhenhong chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT youlu chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT yunfan chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT jianyingzhou chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT zheliu chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT juanli chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT yilongwu chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT chinesethoraciconcologygroupctong chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib AT chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinibworkgroup chineseexpertconsensusonmanagementofspecialadverseeffectsassociatedwithlorlatinib |